ERBB2 and non-small cell lung carcinoma: The first one, by Mateo et al., included 174 patients with metastatic NSCLC and tested them for 29 DNA alterations using an NGS panel (the panel included EGFR, BRAF, ERBB2, TP53) and three ARN fusions, namely, ALK, ROS, RET. It aimed to determine the cost-effectiveness by analyzing the proportion of patients who would not have had detected the gene alteration had it not been for this test by reporting the actual financial burden and the time needed until the results were available [46].